NCT02221622View on ClinicalTrials.gov

Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Mild Cognitive ImpairmentAlzheimer Disease
Interventions
DRUG

Allopregnanolone injection (intravenous solution)

Allopregnanolone intravenous infusion

DRUG

Placebo injection (intravenous solution)

Placebo intravenous infusion

Trial Locations (1)

90033

University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II, Los Angeles

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Southern California

OTHER

NCT02221622 - Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD | Biotech Hunter | Biotech Hunter